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Inhibition to repair DNA metabolism to respond to damaged DNA
can lead to genetic instability, resulting in cancer cell death (Audeh
et al., 2010; Bryant et al., 2005; Farmer et al., 2005; Lukas et al.,
2003; Tutt et al., 2010) [1,2,6,8,11]. Despite of various studies
demonstrating efﬁciency of combination therapy through down-
regulation of DNA repair pathway, the suppression effects of DNA
repair pathway by chemotherapeutic agents from natural bioactive
compounds are less understood (Eitsuka et al., 2014; Kastan et al.,
2004; Kawabata et al., 2000; Mancuso et al., 2014) [5,7,9].
Here, the data shows that ferulic acid reduced the S-phases
post to UV treatment in breast cancer cells and was hypersensitive
in breast cancer cells, MDA-MB-231.
& 2016 The Author. Published by Elsevier Inc. This is an open
access article under the CC BY license
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Value of the data
 The data signiﬁcantly extends ferulic acid treatment in breast cancer chemotherapy.
 The data provides the information of the effect of different UV irradiations in breast cancer cells
with ferulic acid treatment.1. Data
FACS proﬁles showed that ferulic acid in combination with UV irradiation reduced more the S-
phase compared to the cells treated with UV irradiation, as well as in UV untreated cells [3] (Fig. 1).
MDA-MB-231 cells with ferulic acid were more sensitive to UV treatment compared to the cells with
DMSO by performing colony formation assays [4] (See Fig. 2).2. Experimental design, materials and methods
2.1. Cell culture
MDA-MB-231 breast cancer cells were cultured in DMEM (Invitrogen) supplemented with 10%
fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin (Invitrogen) [3,4]. The cells were
cultured with ferulic acid (Sigma) treatment for experiments. Ferulic acid was dissolved in DMSO was
dissolved in PBS for the experiments. All of cell lines were incubated at 37 °C with 5% CO2.-phase cell cycle proﬁles post to UV treatment. MDA-MB-231 cells were cultured with 10 μM
. The cells were exposed to UV treatment and harvested. The cell pellets were ﬁxed in 70% ethanol
analysis. UV-; UV untreated, UVþ; UV treated (20 mJ/s, harvest post to 3 h).
Fig. 2. Breast cancer cells with ferulic acid treatment are highly sensitive to UV treatment. MDA-MB-231 cells were pretreated
with ferulic acid (10 μM) or DMSO for 24 h and re-plated in culture dishes. Then the cells were exposed with UV irradiation
(020 mJ/s). Survival was determined using a colony assay from three independent experiments. The data are mean7-
standard errors. *; po0.05.
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MDA-MB-231 breast cancer cells were pretreated with ferulic acid or DMSO for 24 h. The cells
were exposed to 20 mJ/s UV treatment and harvested post to 3 h. For ﬂuorescence-activated cell
sorting (FACS) analysis, MDA-MB-231 cells were ﬁxed overnight at 4C in 70% ethanol, stained with
propidium iodine (PI) for 1 h. The cells analyzed for DNA content using a FACS Calibur machine (BD
Biosciences).2.3. Colony assay (Cell survival analysis)
MDA-MB-231 breast cancer cells were prepared for colony assay [10]. After the pre-treatments
with ferulic acid or DMSO, the cells were plated in plates with UV irradiation (020 mJ/s). The cells
were cultured for clonogenic assay in triplicates. After 2 weeks in culture, colonies were ﬁxed with
methanol and stained with crystal violet.2.4. Statistical analysis
All data are representative of at least three independent experiments. Data are mean7SEM unless
otherwise indicated. Statistical signiﬁcance of comparison between two groups was determined by
two-tailed Student's t-test where indicated. For comparing more than one group, one-way ANOVA
was used. Signiﬁcant differences were considered at p-values of less than 0.05.Acknowledgments
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Supplementary data associated with this article can be found in the online version at http://dx.doi.
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